April 10, 2024 Epicrispr Biotechnologies to Participate in a Fireside Chat Titled Genetic Medicine for Generalists Hosted by Canaccord
April 9, 2024 Epicrispr Biotechnologies Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
April 1, 2024 Epicrispr Biotechnologies to Participate in a Fireside Chat at the Cantor Virtual Muscular Dystrophy Symposium
March 13, 2024 Epicrispr Biotechnologies to Present at the Upcoming Charles River Cell and Gene Therapy Summit
November 16, 2023 FDA Grants Orphan Drug Designation to EPI-321, Epicrispr Biotechnologies’ Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
October 31, 2023 Kite and Epicrispr Biotechnologies Announce Collaboration to Develop New Cell Therapies for Cancer
October 26, 2023 Epicrispr Biotechnologies Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
October 19, 2023 Epicrispr Biotechnologies to Present at the Upcoming Annual European Society of Gene and Cell Therapy
October 17, 2023 Epicrispr Biotechnologies Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
October 5, 2023 Epicrispr Biotechnologies to Present at the Upcoming BMO Life Sciences Private Company Showcase
